<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04695327</url>
  </required_header>
  <id_info>
    <org_study_id>TILT-T115</org_study_id>
    <secondary_id>2020-001778-31</secondary_id>
    <nct_id>NCT04695327</nct_id>
  </id_info>
  <brief_title>TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 Monotherapy</brief_title>
  <acronym>TUNIMO</acronym>
  <official_title>A Phase 1, Open-Label, Dose-escalation Clinical Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus (TILT-123) in Patients With Injectable Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TILT Biotherapeutics Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TILT Biotherapeutics Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, phase 1, dose-escalation, multicenter trial evaluating the safety of&#xD;
      oncolytic adenovirus TILT-123 as monotherapy in advanced solid tumor patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, phase 1, dose-escalation trial evaluating the safety of TILT-123 as&#xD;
      monotherapy in advanced solid tumor patients. TILT-123 is an oncolytic adenovirus coding for&#xD;
      tumor necrosis factor alpha and interleukin 2. The trial includes 2 healthcare centers in&#xD;
      Helsinki (Finland). Patients with different indications are expected to be treated in the&#xD;
      trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 11, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with any (serious and non-serious) Adverse Events.</measure>
    <time_frame>85 days</time_frame>
    <description>Safety (I)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with abnormal laboratory values.</measure>
    <time_frame>85 days</time_frame>
    <description>Safety (II)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with vital sign abnormalities.</measure>
    <time_frame>85 days</time_frame>
    <description>Safety (III)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events assessed by 12- lead electrocardiograms (ECGs)</measure>
    <time_frame>85 days</time_frame>
    <description>Safety (IV)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive mulriple administrations of TILT-123.&#xD;
Escalation to the next dose of TILT-123 level will occur when the safety data has been evaluated for all patients in the preceding dose level.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TILT-123</intervention_name>
    <description>TNFalpha and IL-2 coding oncolytic adenovirus TILT-123</description>
    <arm_group_label>Monotherapy</arm_group_label>
    <other_name>TNFalpha and IL-2 coding oncolytic adenovirus TILT-123</other_name>
    <other_name>Ad5/3-E2F-d24-hTNFa-IRES-hIL2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed and dated informed consent before any trial-related activities.&#xD;
&#xD;
          -  Male or female over 18 years of age&#xD;
&#xD;
          -  Pathologically confirmed refractory or recurrent injectable solid tumor, which cannot&#xD;
             be treated with curative intent with available therapies.&#xD;
&#xD;
          -  Standard therapy has failed, it does not exist, is not available or is unlikely to&#xD;
             result in meaningful clinical benefit (as assessed by the investigator). Other&#xD;
             appropriate evidence-based therapies have failed or are contraindicated.&#xD;
&#xD;
          -  Multiple prior therapies (e.g. surgery, chemotherapy, checkpoint inhibitors, kinase&#xD;
             inhibitors, biological therapies, hormonal therapies, radiation, etc) are allowed.&#xD;
&#xD;
          -  At least one tumor (&gt;14 mm in diameter) must be available for injections and biopsies&#xD;
             for correlative analyses. The disease burden must be measurable, but does not need to&#xD;
             fulfil RECIST 1.1.&#xD;
&#xD;
          -  Adequate hepatic and renal functions as following:&#xD;
&#xD;
               1. Platelets &gt; 75 000/mm3&#xD;
&#xD;
               2. Haemoglobin ≥ 100 g/L.&#xD;
&#xD;
               3. AST and ALT &lt; 3 x ULN.&#xD;
&#xD;
               4. GFR &gt;60 ml/min (Cockcroft-Gault formula).&#xD;
&#xD;
               5. Leukocytes (WBC) &gt; 3,0&#xD;
&#xD;
               6. Bilirubin &lt;1,5 x ULN 8. Men and women must be willing to use adequate forms of&#xD;
                  contraception from screening, during the trial, and for a minimum of 90 days&#xD;
                  after end of treatment, in accordance with the following:&#xD;
&#xD;
               1. Women of childbearing potential: Barrier contraceptive method (i.e. condom) must&#xD;
                  be used in addition to one of the following methods: Intrauterine device or&#xD;
                  hormonal contraception (oral contraceptive pills, implant, transdermal patches,&#xD;
                  vaginal ring or long-acting injections).&#xD;
&#xD;
               2. Women not of childbearing potential: Barrier contraceptive method (i.e. condom)&#xD;
                  must be used.&#xD;
&#xD;
               3. Men: Barrier contraceptive method (i.e. condom) must be used.&#xD;
&#xD;
          -  Demonstrated WHO/ECOG performance score of 0-1 at screening.&#xD;
&#xD;
          -  Life expectancy time longer than 3 months.&#xD;
&#xD;
          -  Capable of understanding and complying with parameters as outlined in the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of immunosuppressive medications (corticosteroids or drugs used in treatment of&#xD;
             autoimmune disease). Exempted are the following which can be allowed at screening and&#xD;
             during the trial: a) replacement corticosteroids if e.g. the patient has adrenal&#xD;
             insufficiency after prior immunotherapy b) inhaled and topical treatments c) up to 20&#xD;
             mg per day of prednisone/prednisolone.&#xD;
&#xD;
          -  Treated with any anti-cancer therapy within 30 days prior to the first virus&#xD;
             injection. Anti-cancer therapy is defined as anti-cancer agents (e.g. cytotoxic&#xD;
             chemotherapy, immunotherapy, signal-transduction inhibitors, etc) and investigational&#xD;
             agents. An investigational agent is any drug or therapy that is currently not approved&#xD;
             for use in humans. Continuation of hormonal therapy or use of bone modifying agents&#xD;
             (eg. bisphosphonate or denosumab) is allowed if started at least 3 months before.&#xD;
             Palliative radiation is not allowed within 14 days of the first virus injection&#xD;
             (before or after), but it is allowed after day 15 during the trial treatment period,&#xD;
             if deemed necessary by the investigator.&#xD;
&#xD;
          -  Uncontrolled cardiac or vascular diseases.&#xD;
&#xD;
          -  History of myocardial infarction or cerebral stroke within the previous 12 months&#xD;
             before screening or is not sufficiently recovered from an older infarction or cerebral&#xD;
             stroke.&#xD;
&#xD;
          -  History of severe hepatic dysfunction, hepatitis or HIV.&#xD;
&#xD;
          -  History of coagulation disorder.&#xD;
&#xD;
          -  Any other medical condition or laboratory abnormality that in the judgment of the&#xD;
             principal investigator, may increase the risk associated with study participation or&#xD;
             may interfere with interpretation of study results and /or otherwise make the patient&#xD;
             inappropriate for entry into this trial.&#xD;
&#xD;
          -  Female patients who are pregnant, breastfeeding or intend to become pregnant.&#xD;
&#xD;
          -  Untreated brain metastases. Treated brain metastases which have not progressed in 3&#xD;
             months prior to screening are allowed.&#xD;
&#xD;
          -  Previously treated (within 5 years) with any oncolytic or replication deficient&#xD;
             adenovirus.&#xD;
&#xD;
          -  Allergy to ingredients present in the investigational medicinal products (ingredients&#xD;
             are listed in the protocol).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katriina Peltola, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tuomo Alanko, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Docrates Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Docrates Cancer Center</last_name>
    <phone>+358 107732050</phone>
    <email>hospital@docrates.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Helsinki University Hospital</last_name>
    <phone>+358 947173197</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <state>Uusima</state>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katriina Peltola, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Docrates Cancer Center</name>
      <address>
        <city>Helsinki</city>
        <state>Uusima</state>
        <zip>00180</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tuomo Alanki, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 4, 2021</study_first_submitted>
  <study_first_submitted_qc>January 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2021</study_first_posted>
  <last_update_submitted>May 19, 2021</last_update_submitted>
  <last_update_submitted_qc>May 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oncolytic virus</keyword>
  <keyword>Virotherapy</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Adenovirus</keyword>
  <keyword>TILT-123</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoviridae Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

